Solano Clinical Research (A Division of Dow Pharmaceutical Sciences)
Davis, California, 95616, United States
NCT Number: NCT00198419
The objective of this study was to rule out a greater than 10% incidence of hypersensitivity to Vitrase following a single intradermal injection of 3 USP units Vitrase. Less than or equal to 10% hypersensitivity response was considered acceptable.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Davis, California, 95616, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: ovine hyaluronidase
Time frame: 1-2 days
hypersensitivity to Vitrase following a single intradermal injection of 3 USP Units Vitrase
Bausch & Lomb Incorporated
Industry
Clinical Evaluation of Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase) Open Label, Normal Volunteer Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03771118
Chemically-Induced Disorders, Drug Hypersensitivity
Montpellier, France
View Trial DetailsNCT07069439
Allergy and Immunology, Caregivers
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT02839551
Chemically-Induced Disorders, Drug Hypersensitivity
Montpellier, France
View Trial DetailsNCT06428162
Chemically-Induced Disorders, Drug Abuse
Minya, Egypt
View Trial Details